Administration of alemtuzumab and G-CSF to adults with relapsed or refractory acute lymphoblastic leukemia: Results of a phase II study

European Journal of Haematology

Volumn 91, Issue 4, 2013, Pages 315-321

  Gorin, Norbert Claude ^a   Isnard, Françoise ^a   Garderet, Laurent ^a   Ikhlef, Souhila ^a   Corm, Selim ^b   Quesnel, Bruno ^b   Legrand, Ollivier ^a   Cachanado, Marine ^a   Rousseau, Alexandra ^a   Laporte, Jean Philippe ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Acute lymphoblastic leukemia; Alemtuzumab

Indexed keywords

ALEMTUZUMAB; ALLOPURINOL; COTRIMOXAZOLE; FLUCONAZOLE; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; URATE OXIDASE; VALACICLOVIR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ADULT DISEASE; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; BLAST CELL; BRONCHOSPASM; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CHILL; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DONOR LYMPHOCYTE INFUSION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG TOLERANCE; FEMALE; FEVER; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LUNG ASPERGILLOSIS; LUNG INFECTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; PNEUMOCYSTOSIS; PRIORITY JOURNAL; PROPHYLAXIS; RASH; SUPPLEMENTATION; TUMOR LYSIS SYNDROME;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALEMTUZUMAB;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CYTOTOXICITY, IMMUNOLOGIC; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GENE EXPRESSION; GLYCOPROTEINS; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; NEUTROPHILS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENCE; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84884820093     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12154     Document Type: Article

References (25)

1. Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol 2011;29:532-43.
2. Gorin NC, Labopin M, Polge E, et al. Risk assessment in adult acute lymphoblastic leukaemia before early haemopoietic stem cell transplantation with a geno-identical donor: an easy clinical prognostic score to identify patients who benefit most from allogeneic haemopoietic stem cell transplantation. Leukemia 2003;17:1596-9.
3. Hale G, Swirsky D, Waldmann H, Chan LC. Reactivity of rat monoclonal antibody CAMPATH-1 with human leukaemia cells and its possible application for autologous bone marrow transplantation 3. Br J Haematol 1985;60:41-8.
4. Waldmann H, Cobbold S, Wilson A, et al. Rat monoclonal antibodies for bone marrow transplantation-the CAMPATH series 5. Adv Exp Med Biol 1985;186:869-75.
5. Zhang Z, Zhang M, Goldman CK, Ravetch JV, Waldmann TA. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H. Cancer Res 2003;63:6453-7.
6. Laporte JP, Isnard F, Garderet L, Fouillard L, Gorin NC. Remission of adult acute lymphocytic leukaemia with alemtuzumab. Leukemia 2004;18:1557-8.
7. Piccaluga PP, Martinelli G, Malagola M, et al. Anti-leukemic and anti-GVHD effects of campath-1H in acute lymphoblastic leukemia relapsed after stem-cell transplantation. LeukLymphoma 2004;45:731-3.
8. Piccaluga PP, Martinelli G, Malagola M, et al. Alemtuzumab in the treatment of relapsed acute lymphoid leukaemia 3. Leukemia 2005;19:135.
9. Stockmeyer B, Elsasser D, Dechant M, et al. Mechanisms of G-CSF- or GM-CSF-stimulated tumor cell killing by Fc receptor-directed bispecific antibodies. J Immunol Methods 2001;2:103-11.
10. Horner H, Frank C, Dechant C, et al. Intimate cell conjugate formation and exchange of membrane lipids precede apoptosis induction in target cells during antibody-dependent, granulocyte-mediated cytotoxicity. J Immunol 2007;179:337-45.
11. Hale G, Xia MQ, Tighe HP, Dyer MJ, Waldmann H. The CAMPATH-1 antigen (CDw52). Tissue Antigens 1990;35:118-27.
12. Waldmann H, Hale G. CAMPATH: from concept to clinic. Philos Trans R Soc Lond B Biol Sci 2005;360:1707-11.
13. Dearden CE, Matutes E, Cazin B, et al. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood 2001;98:1721-6.
14. Keating MJ, Cazin B, Coutre S, et al. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Oncol 2002;20:205-13.
15. Avivi I, Chakrabarti S, Kottaridis P, et al. Neurological complications following alemtuzumab-based reduced-intensity allogeneic transplantation. Bone Marrow Transplant 2004;34:137-42.
16. Tibes R, Keating MJ, Ferrajoli A, et al. Activity of alemtuzumab in patients with CD52-positive acute leukemia 3. Cancer 2006;106:2645-51.
17. Angiolillo AL, Yu AL, Reaman G, Ingle AM, Secola R, Adamson PC. A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: a Children's Oncology Group report. PediatrBlood Cancer 2009;53:978-83.
18. Siders WM, Shields J, Garron C, et al. Involvement of neutrophils and natural killer cells in the anti-tumor activity of alemtuzumab in xenograft tumor models. Leuk Lymphoma 2010;51:1293-304.
19. Hu Y, Gale M, Shields J, et al. Enhancement of the anti-tumor activity of therapeutic monoclonal antibodies by CXCR4 antagonists. Leuk Lymphoma 2012;53:130-8.
20. van der Velden VH. Cytotoxicity of Campath-1H for acute lymphoblastic leukemia cells carrying the t(12;21) translocation. Haematologica 2006;91:291A.
21. Weidmann E, Hess G, Chow KU, et al. A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas. LeukLymphoma 2010;51:447-55.
22. Buyck HC, Prentice HG, Griffiths PD, Emery VC. The risk of early and late CMV DNAemia associated with Campath use in stem cell transplant recipients. Bone Marrow Transplant 2010;45:1212-9.
23. Nijmeijer BA, van Schie ML, Halkes CJ, Griffioen M, Willemze R, Falkenburg JH. A mechanistic rationale for combining alemtuzumab and rituximab in the treatment of ALL 1. Blood 2010;116:5930-40.
24. Kantarjian H, Thomas D, Jorgensen J, et al. Inotuzumab ozogamicin, an anti-CD22-calicheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol 2012;13:403-11.
25. Topp MS, Gökbuget N, Zugmaier G, et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 2012;120:5185-7.